BLUE - bluebird bio net loss narrows as it reports product revenue for first time

bluebird bio (NASDAQ:BLUE) saw its Q4 2021 net loss narrow ~22% as it posted product revenue for the first time. Its quarterly net loss was ~$155.1M, or -$2.14 per basic and diluted share. The company reported $1.4M in product revenue from its gene therapy beti-cel (betibeglogene autotemcel) for ?-thalassemia, which is only approved in the European Union. Operating expenses declined ~3% year over year to $137.3M. The company ended the year with $396.6M in cash. Looking ahead, bluebird bio (BLUE) is looking forward to U.S. FDA action dates of Aug. 19 for beti-cel and Sept. 16 for eli-cel (elivaldogene autotemcel) for cerebral adrenoleukodystrophy Read why LB Research argues that bluebird bio (BLUE) is a hold.

For further details see:

bluebird bio net loss narrows as it reports product revenue for first time